Creative Commons source reading · Epilepsy and seizure classification
Deep brain stimulation of the anterior nucleus of the thalamus for drug-resistant epilepsy.
Tim A M Bouwens van der Vlis; Olaf E M G Schijns; Frédéric L W V J Schaper; Govert Hoogland; Pieter Kubben; Louis Wagner; Rob Rouhl; Yasin Temel; Linda Ackermans
Originally published in Neurosurgical review · 2018-01-06
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Despite the use of first-choice anti-epileptic drugs and satisfactory seizure outcome rates after resective epilepsy surgery, a considerable percentage of patients do not become seizure free. ANT-DBS may provide for an alternative treatment option in these patients. This literature review discusses the rationale, mechanism of action, clinical efficacy, safety, and tolerability of ANT-DBS in drug-resistant epilepsy patients. A review using systematic methods of the available literature was performed using relevant databases including Medline, Embase, and the Cochrane Library pertaining to the different aspects ANT-DBS. ANT-DBS for drug-resistant epilepsy is a safe, effective and well-tolerated therapy, where a special emphasis must be given to monitoring and neuropsychological assessment of both depression and memory function. Three patterns of seizure control by ANT-DBS are recognized, of which a delayed stimulation effect may account for an improved long-term response rate.
Methods
Literature for this review was identified searching Medline, Embase, and the Cochrane Library databases from the date of the first available article until September 2017. The following keywords were queried either individually or combined: deep brain stimulation, epilepsy, anterior nucleus of the thalamus, complications, and mechanism of action. The search was limited to studies published in English.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
